Joyce F. Liu
YOU?
Author Swipe
View article: 547 A phase 1b study of intraperitoneal cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in platinum resistant ovarian cancer
547 A phase 1b study of intraperitoneal cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in platinum resistant ovarian cancer Open
View article: Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 <sup>+</sup> and PD-1 <sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 <sup>+</sup> and PD-1 <sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors Open
PURPOSE Retrospective studies have found associations between the number of intratumoral immune cells and patient outcomes for specific cancers treated with targeted therapies. However, the clinical value of routinely quantifying intratumo…
View article: Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub>degradation to overcome cancer chemoresistance
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X<sub>L</sub>degradation to overcome cancer chemoresistance Open
Paclitaxel and other microtubule-targeting agents are cornerstone therapies for diverse cancers, including lung, breast, cervical, pancreatic, and ovarian malignancies. Paclitaxel induces tumor cell apoptosis during mitosis by disrupting m…
View article: Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Figure 2. Hazard Ratio estimates in subgroup analysis based on the stratification factors. Hazard ratios (HR) are estimated with a proportional hazards model stratified by prior exposure to PARP inhibitor (PARPi) (yes vs no) …
View article: Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 1. Baseline Patient Characteristics
View article: Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 3. Experimental Arm Hazard Ratio Estimates for interim analysis (N = 120)
View article: Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Table 2: Representativeness of Study Participants
View article: Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Supplementary Figure 1. Progression-free survival and overall survival by randomized treatment (N = 120). Distributions were estimated utilizing the Kaplan-Meier method for progression-free survival (PFS) by investigator assessment. Hazard…
View article: Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Appendix
View article: Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Open
Purpose:We assessed the efficacy of anti–PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior beva…
View article: Shedding LIGHT on the changing landscape of poly‐ADP ribose polymerase inhibitors in ovarian cancer
Shedding LIGHT on the changing landscape of poly‐ADP ribose polymerase inhibitors in ovarian cancer Open
The landscape of poly‐ADP ribose polymerase (PARP) inhibitor use in ovarian cancer has evolved since the LIGHT study was designed. However, this study still provides valuable insight into biomarkers of PARP inhibitor activity and associati…
View article: Phase 2 Study of Wee1 Inhibitor Adavosertib in Recurrent Uterine Carcinosarcoma
Phase 2 Study of Wee1 Inhibitor Adavosertib in Recurrent Uterine Carcinosarcoma Open
View article: Using hidden Markov modelling to reveal in-session stages in text-based counselling
Using hidden Markov modelling to reveal in-session stages in text-based counselling Open
Counselling sessions have multiple stages, each with its themes and objectives. This study aimed to apply Hidden Markov Models (HMMs) to analyse counselling sessions from Open Up, an online text-based counselling platform in Hong Kong. The…
View article: Supplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Supplementary Table 3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
CRISPR dropout scores for USP1 and UAF1
View article: Supplementary Figure S4 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Figure S4 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Supplementary Figure S4. USP1 inhibitor and a PARP inhibitor combination treatment is well tolerated in mice
View article: Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Cell line vendor and growth media
View article: Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Data from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining DNA repair processes. This phenomenon is exemplifi…
View article: Supplementary Figure S3 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Figure S3 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Supplementary Figure S3. USP1 inhibitor exhibits synergistic activity with a POLQ inhibitor in BRCA1-deficient preclinical models
View article: Data from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Data from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Recent studies suggest that PARP and POLQ inhibitors confer synthetic lethality in BRCA1-deficient tumors by accumulation of single-stranded DNA (ssDNA) gaps at replication forks. Loss of USP1, a deubiquitinating enzyme, is also synthetica…
View article: Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Mouse body weight measurements following treatment with KSQ-4279 and olaparib
View article: Supplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Supplementary Table 2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
List of antibodies used for immunoblotting
View article: Supplementary Table S1 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Table S1 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
CRISPR screen results in UWB1.289 cells treated with USP1 inhibitor versus DMSO
View article: Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Enzyme kinetic studies of KSQ-4279
View article: Supplementary Materials and Methods from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Materials and Methods from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Supplementary Materials and Methods
View article: Supplementary Table S3 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Table S3 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Clinical characteristics of tumor samples used to generate patient derived organoids
View article: Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Clonogenic assays in the presence of KSQ-4279 and olaparib in combination
View article: Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Combination studies using KSQ-4279 and PARP inhibitors
View article: Supplementary Table S2 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
Supplementary Table S2 from Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity Open
Mass spectrometry of proteins captured using aniPOND method in samples treated with USP inhibitor versus untreated samples.
View article: Figure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
USP1/UAF1 CRISPR dependency profiles
View article: Figure S6 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Figure S6 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors Open
Western blot analysis of sensitive and insensitive cell lines to USP1 inhibition